182 related articles for article (PubMed ID: 4115582)
1. Generic equivalence and non-equivalence of drugs.
Smith RN
Lancet; 1972 Sep; 2(7776):528-30. PubMed ID: 4115582
[No Abstract] [Full Text] [Related]
2. Biologic availability and therapeutic equivalence.
Arnold JD; Sicé J
J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):546-9. PubMed ID: 977793
[No Abstract] [Full Text] [Related]
3. Bioavailability of drugs (second of two parts).
Koch-Weser J
N Engl J Med; 1974 Sep; 291(10):503-6. PubMed ID: 4604153
[No Abstract] [Full Text] [Related]
4. FDA moves closer to new requirements for NTI drugs.
Traynor K
Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
[No Abstract] [Full Text] [Related]
5. FDA mulls changes to bioequivalence standards.
Traynor K
Am J Health Syst Pharm; 2010 Jun; 67(11):864. PubMed ID: 20484205
[No Abstract] [Full Text] [Related]
6. Bioavailability and bioequivalence.
Skelly JP
J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):539-45. PubMed ID: 977792
[No Abstract] [Full Text] [Related]
7. Generic equivalents: issues and concerns.
Lamy PP
J Clin Pharmacol; 1986; 26(5):309-16. PubMed ID: 3700686
[TBL] [Abstract][Full Text] [Related]
8. Aspects of availability.
Lancet; 1973 Feb; 1(7797):245. PubMed ID: 4119386
[No Abstract] [Full Text] [Related]
9. Therapeutic non-equivalence.
Br Med J; 1972 Sep; 3(5827):599-600. PubMed ID: 5071688
[No Abstract] [Full Text] [Related]
10. The debate over substitution policy. Its evolution and scientific basis.
Schwartz LL
Am J Med; 1985 Aug; 79(2B):38-44. PubMed ID: 3898831
[TBL] [Abstract][Full Text] [Related]
11. Drug product equivalence--are specifications necessary?
Bergen JV
J Am Pharm Assoc; 1972 Jan; 12(1):21-5. PubMed ID: 5007259
[No Abstract] [Full Text] [Related]
12. [Biologic availability of drugs in humans and animals].
Wichliński L
Pol Tyg Lek; 1975 Dec; 30(50):2111-2. PubMed ID: 1197106
[No Abstract] [Full Text] [Related]
13. Bioavailability of drugs: principles and problems. Report of a WHO Scientific Group.
World Health Organ Tech Rep Ser; 1973 Nov; 536():1-17. PubMed ID: 4204708
[No Abstract] [Full Text] [Related]
14. A scientific rationale for choosing patients rather than normal subjects for Phase I studies.
Oates JA
Clin Pharmacol Ther; 1972; 13(5):809-11. PubMed ID: 5054325
[No Abstract] [Full Text] [Related]
15. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
Marsh DA; Hoar ME
Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability and pharmacokinetic analysis of drug responding systems.
Smolen VF
Annu Rev Pharmacol Toxicol; 1978; 18():495-522. PubMed ID: 348066
[No Abstract] [Full Text] [Related]
17. A time to speak out on bioequivalence and therapeutic equivalence.
Dettelbach HR
J Clin Pharmacol; 1986; 26(5):307-8. PubMed ID: 2871052
[No Abstract] [Full Text] [Related]
18. Bioavailability of drugs (first of two parts).
Koch-Weser J
N Engl J Med; 1974 Aug; 291(5):233-7. PubMed ID: 4600408
[No Abstract] [Full Text] [Related]
19. Bioinequivalence and drug toxicity. How great is the problem and what can be done?
Gleiter CH; Gundert-Remy U
Drug Saf; 1994 Jul; 11(1):1-6. PubMed ID: 7917077
[No Abstract] [Full Text] [Related]
20. Mental health and the elderly: new biopharmaceutic considerations.
Cabana BE
Health Aff (Millwood); 1983; 2(3):33-8. PubMed ID: 6654313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
